Bruker vs Madrigal Pharmaceuticals

Bruker (BRKR), health care, and Madrigal Pharmaceuticals (MDGL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Madrigal Pharmaceuticals is worth $9.8B on the stock market and Bruker $9.4B: Madrigal Pharmaceuticals is valued at 5% more. Bruker's operating margin in its latest fiscal year was 1.98% and Madrigal Pharmaceuticals's -31.3%. Over the past year Bruker's share price has moved +42.1% and Madrigal Pharmaceuticals's -24.2%.

Key facts

Bruker market value
$9.4B
Madrigal Pharmaceuticals market value
$9.8B
Bruker revenue
$3.4BFY to 2025-12-31
Madrigal Pharmaceuticals revenue
$958.4MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Bruker vs Madrigal Pharmaceuticals: every measure side by side
Measure Bruker Madrigal Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$9.4Blower$9.8Bhigher
Revenue$3.4Bhigher$958.4Mlower
Earnings-$8.6Mhigher-$288.3Mlower
Employees11,085higher915lower
Total assets$6.2Bhigher$1.3Blower
Valuation
P/E——
P/S2.7lower10.2higher
P/B4.1lower15.6higher
Dividend yield0.08%higher0.00%lower
Profitability
Operating margin1.98%higher-31.3%lower
Balance sheet
Net assets$2.5Bhigher$602.7Mlower
Total liabilities$3.7Bhigher$656.9Mlower
Total debt$1.9Bhigher$339.9Mlower
Cash on hand$298.8Mhigher$198.7Mlower
Price change
Today+1.22%higher-0.46%lower
1 year+42.1%higher-24.2%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Madrigal Pharmaceuticals only (5)

Percentages are each holding's share of that investor's reported portfolio. Who owns BRKR · Who owns MDGL

Further comparisons

Learn

Questions and answers

Which is bigger, Bruker or Madrigal Pharmaceuticals?

By market value, Madrigal Pharmaceuticals is the larger: $9.8B against $9.4B for Bruker. By revenue in its latest fiscal year, Bruker is the larger: $3.4B against $958.4M for Madrigal Pharmaceuticals.

Which has the higher operating margin?

Bruker: 1.98%, against -31.3% for Madrigal Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Bruker: 0.08%, against 0.00% for Madrigal Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Bruker: $1.9B, against $339.9M for Madrigal Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bruker and Madrigal Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Bruker and 5 hold Madrigal Pharmaceuticals.

Cite this page

Funkfolio, “Bruker vs Madrigal Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/brkr-vs-mdgl

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.